MORGANTOWN — West Virginia University, California-based biotech company Gilead Sciences and community organizations are teaming to fight back against one of the less spoken about side effects of the opioid epidemic.

The drug crisis has precipitated a sharp rise in the number of people infected with the hepatitis c virus, or HCV, through the exchange of syringes, effectively creating a crisis within a crisis. However, multiple parties gathered in Morgantown Wednesday morning for the launch of HepConnect, an effort designed to address HCV rates through a multi-pronged approach.

Business Editor Conor Griffith can be reached by at 304-395-3168 or by email at cgriffith@statejournal.com

You must be logged in to react.
Click any reaction to login.
0
0
0
0
0

Recommended for you

Load comments